Merck builds on strong 2019 with plan to spin out legacy brands

5 February 2020

New Jersey, USA-based drugmaker Merck & Co (NYSE: MRK) has posted revenues of $11.9 billion for the last quarter of 2019, matching analysts’ expectations, making full-year revenues of $46.8 billion.

At the same time, the company announced it would spin off over $6 billion worth of assets in order to focus on what it sees as key growth pillars for the future.

Following generally accepted accounting principles (GAAP), Merck reported earnings per share of $0.92 for the fourth quarter and $3.81 for the full year of 2019.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK